Trial Profile

Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessiting a Neo-Adjuvant Chemotherapy.

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
Indications Breast cancer
Focus Therapeutic Use
Acronyms SPAM

Most Recent Events

31 Jul 2012 Biomarkers information updated
30 Jul 2012 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov record.
17 Jun 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com